MiMedx Group, Inc. (MDXG) Stock Score, Valuation & Financial Research
MiMedx Group, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 66/100.
Quick answer for MDXG
MiMedx Group, Inc. currently has a Wall Street Score of 66/100. The stored market price is $4.73. Its financial score is 39/100. Its valuation score is 97/100. These figures are a research snapshot, not a buy or sell recommendation.
What MiMedx Group, Inc. does
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surg
MDXG financial snapshot
- Wall Street Score:
- 66/100
- Current price:
- $4.73
- Market capitalization:
- $689.4M
- Revenue:
- $389.4M
- Net income:
- $30.7M
- Free cash flow:
- $73.0M
- Cash:
- $159.8M
- Total debt:
- $17.6M
- EPS:
- 0.33
- P/E ratio:
- 14.3x
- Financial score:
- 39/100
- Valuation score:
- 97/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $73.0M, showing positive cash generation.
- The balance sheet shows $159.8M of cash versus $17.6M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 97/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MDXG
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.